Publications by authors named "Miran Sebestjen"

Claim this Profile
S
SGLT2 Inhibitors Are Associated with Left Ventricular Reverse Remodeling in Patients with Non-Compaction Cardiomyopathy-A Prospective Observational Cohort Trial.
Andraž Cerar, Gregor Poglajen, Gregor Zemljič, Sabina Frljak, Neža Žorž

Biomedicines· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of LDL cholesterol and Lp(a) on monocytes and macrophages in atherosclerosis.
Sabina Ugovšek, Jernej Jeras, Miran Šebeštjen, Janja Zupan

Biochem Med (Zagreb)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal Response to Levosimendan in Advanced Chronic Heart Failure Patients Listed for Heart Transplantation Predicts Early Postoperative Renal Function Course.
Gregor Zemljic, Gregor Poglajen, Sabina Frljak, Andraz Cerar, Renata Okrajsek, Miran Sebestjen

J Cardiovasc Dev Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gain of function variants in PCSK9 gene in high risk patients after myocardial infarction with increased lipoprotein (a) values and treated with statins.
Sabina Ugovšek, Andreja Rehberger Likozar, Tina Levstek, Katarina Trebušak Podkrajšek, Janja Zupan

Sci Rep· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial.
Andreja Rehberger Likozar, Tina Levstek, Tina Karun, Katarina Trebušak Podkrajšek, Janja Zupan

Eur J Med Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of PCSK9 Inhibitors on Regulators of Lipoprotein Homeostasis, Inflammation and Coagulation.
Patricija Lunar, Hana Meglič, Mateja Vehar, Sabina Ugovšek, Andreja Rehberger Likozar

Biomedicines· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients.
Andreja Rehberger Likozar, Sabina Ugovšek, Miran Šebeštjen

Eur J Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haplotype of the Lipoprotein(a) Gene Variants rs10455872 and rs3798220 Is Associated with Parameters of Coagulation, Fibrinolysis, and Inflammation in Patients after Myocardial Infarction and Highly Elevated Lipoprotein(a) Values.
Sabina Ugovšek, Andreja Rehberger Likozar, Tina Levstek, Katarina Trebušak Podkrajšek, Janja Zupan

Int J Mol Sci· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smoking and Diabetes Attenuate Number of CD34 Haematopoietic Stem Cells in Peripheral Blood of Patients with Advanced Peripheral Artery Disease.
Barbara Sernek, Rok Kamnikar, Miran Sebestjen, Anja Boc, Vinko Boc

Int J Mol Sci· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors.
Andreja Rehberger Likozar, Miran Šebeštjen

Cardiovasc Ultrasound· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors.
Tina Levstek, Tina Karun, Andreja Rehberger Likozar, Miran Šebeštjen, Katarina Trebušak Podkrajšek

Genes (Basel)· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCSK9 as an Atherothrombotic Risk Factor.
Tadeja Sotler, Miran Šebeštjen

Int J Mol Sci· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atherosclerotic Cardiovascular Disease: Risk Assessment, Prevention and Treatment Strategies.
Jernej Jeras, Sabina Ugovšek, Andreja Rehberger Likozar, Miran Šebeštjen

J Cardiovasc Dev Dis· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels.
Andreja Rehberger Likozar, Miran Šebeštjen

Atheroscler Plus· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TNF-α Predicts Endothelial Function and Number of CD34 Cells after Stimulation with G-CSF in Patients with Advanced Heart Failure.
Sabina Ugovšek, Andreja Rehberger Likozar, Sanjo Finderle, Gregor Poglajen, Renata Okrajšek

J Cardiovasc Dev Dis· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologic modulation of intracellular Na concentration with ranolazine impacts inflammatory response in humans and mice.
Max Lenz, Manuel Salzmann, Cosmin I Ciotu, Christoph Kaun, Konstantin A Krychtiuk, Miran Sebestjen

Proc Natl Acad Sci U S A· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors.
Katja Hrovat, Andreja Rehberger Likozar, Janja Zupan, Miran Šebeštjen

J Cardiovasc Dev Dis· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall.
Sabina Ugovšek, Miran Šebeštjen

J Clin Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Influence of Treatment with PCSK9 Inhibitors and Variants in the (rs1800947), (rs1800629), and (rs1800795) Genes on the Corresponding Inflammatory Markers in Patients with Very High Lipoprotein(a) Levels.
Tina Levstek, Nik Podkrajšek, Andreja Rehberger Likozar, Miran Šebeštjen, Katarina Trebušak Podkrajšek

J Cardiovasc Dev Dis· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Genotypes and Haplotypes Are Associated with Lipoprotein(a) Levels but Not Arterial Wall Properties in Stable Post-Coronary Event Patients with Very High Lipoprotein(a) Levels.
Andreja Rehberger Likozar, Aleš Blinc, Katarina Trebušak Podkrajšek, Miran Šebeštjen

J Cardiovasc Dev Dis· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation.
Sabina Ugovšek, Miran Šebeštjen

Biomolecules· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of lipid-lowering drugs on inflammation: what is yet to be done?
Sabina Ugovšek, Janja Zupan, Andreja Rehberger Likozar, Miran Šebeštjen

Arch Med Sci· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stem Cell Therapy for Chronic and Advanced Heart Failure.
Gregor Poglajen, Sabina Frljak, Gregor Zemljič, Andraž Cerar, Renata Okrajšek

Curr Heart Fail Rep· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options.
Andreja Rehberger Likozar, Mark Zavrtanik, Miran Šebeštjen

Ann Med· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Effects of Angiotensin Receptor-Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction.
Gregor Poglajen, Ajda Anžič-Drofenik, Gregor Zemljič, Sabina Frljak, Andraž Cerar

Diagnostics (Basel)· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis